CMClaudio Marra

Claudio Marra

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Claudio Marra has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cardiac Rehabilitation After Left Ventricular Assist Device Implantation: A Narrative Review

    by Rita Gravino, Luigi Falco, Dario Catapano, Cristiano Amarelli, Fabio Valente, Marina Verrengia, Claudio Marra, Emilio Di Lorenzo, Pierino Di Silverio, Michelle Kittleson, et al.

    Over the past decade, given safety, reduced heart failure-related hospitalizations, and, above all, 5-year mortality rates nearly identical to those of heart transplants, left ventricular assist devices (LVADs) have increasingly become a treatment option for patients with advanced heart failure. However, improvements in functional capacity after LVAD implantation are minimal or modest, depending on pre-implantation right ventricular function, the patient’s hemodynamic status, the optimization of guideline-directed medical therapy, and noncardiac factors (physical deconditioning, skeletal muscle alterations, anemia, and alterations in alveolar gas exchange). Therefore, cardiac rehabilitation (CR) is a fundamental element from the early stages after LVAD implantation, as it is not only safe but also highly effective, leading to improved functional capacity and fewer episodes of worsening heart failure, and may be associated with reduced mortality. To perform safe and effective CR in patients with LVADs, it is crucial to account for the unique issues in this group. This includes the difficulty of detecting an arterial pulse with standard tools during CPR and the importance of closely monitoring the transmission line and LVAD controller to prevent unintended damage. Overall, the clinical trial indicates that exercise-based CR has the potential to improve functional capacity. Furthermore, some data suggest that CR is associated with fewer HF-related hospitalizations and may be linked to lower mortality; however, there is no consensus on this matter, partly because most studies supporting this assertion are observational.


  • Open Access

    Heart Transplant: A Never-Ending Story

    by Daniele Masarone, Rita Gravino, Luigi Falco, Dario Catapano, Cristiano Amarelli, Angelo Caiazzo, Claudio Marra, Michelle Kittleson, Pierino Di Silverio, Emilio Di Lorenzo

    Despite ongoing advancements in the field of heart failure, heart transplantation remains the definitive treatment for patients with advanced heart failure. Decades of research, surgical innovation, and progress in transplant immunology have enabled the overcoming of persistent challenges associated with this complex procedure. Since the initial preclinical experiments involving heart transplants in canines and primates, the process has been profoundly transformed through the development of the bioptome for endomyocardial biopsies and the introduction of immunosuppressive therapies. More recently, improvements in the preservation and transportation of donor hearts, as well as the utilization of cell-free DNA for evaluating graft rejection, are laying the groundwork for further advancements in non-invasive rejection diagnosis and the expansion of the donor pool.


  • Open Access

    The Total Artificial Heart: A Historical Perspective

    by Daniele Masarone, Rita Gravino, Luigi Falco, Dario Catapano, Fabio Valente, Cristiano Amarelli, Claudio Marra, Michelle Kittleson, Pierino Di Silverio, Emilio di Lorenzo

    Scientists, physicians, and engineers have long endeavored to develop a device capable of replacing the function of the heart. The objective is to create a machine or pump for patients suffering from advanced biventricular heart failure, where survival until transplantation is feasible. These total artificial hearts are designed to sustain the patient until a donor heart becomes available. This review aims to present an overview and historical context of the development of the total artificial heart, analyze the currently utilized devices, and briefly discuss future technological innovations in total artificial heart systems.


  • Open Access

    The Prognostic Role of Pulmonary Arterial Elastance in Patients Undergoing Left Ventricular Assist Device Implantation: A Pilot Study

    by Marco Di Mauro, Michelle Kittleson, Giulio Cacioli, Vito Piazza, Rita Lucia Putini, Rita Gravino, Vincenzo Polizzi, Andrea Montalto, Marina Comisso, Fabio Sbaraglia, et al.

    Background: Pulmonary arterial elastance (Ea) is a helpful parameter to predict the risk of acute postoperative right ventricular failure (RVF) after left ventricular assist device (LVAD) implantation. A new method for calculating Ea, obtained by the ratio between transpulmonary gradient and stroke volume (EaB), has been proposed as a more accurate measure than the Ea obtained as the ratio between pulmonary artery systolic pressure and stroke volume (EaC). However, the role of EaB in predicting acute RVF post-LVAD implantation remains unclear. Methods and Results: A total of 35 patients who underwent LVAD implantation from 2018 to 2021 were reviewed in this retrospective analysis. Acute RVF after LVAD implantation occurred in 12 patients (34%): 5 patients with moderate RVF (14% of total) and 7 patients with severe RVF. The EaB was not significantly different between the “severe RVF” vs. “not-severe RVF” groups (0.27 ± 0.04 vs 0.23 ± 0.1, p < 0.403). However, the combination of arterial elastance and central venous pressure was significantly different between the “not-severe RVF” group (central venous pressure < 14 mmHg and EaC < 0.88 mmHg/mL or EaB < 0.24 mmHg/mL; p < 0.005) and the “severe RVF” group (central venous pressure > 14 mmHg and EaC > 0.88 mmHg/mL or EaB > 0.24 mmHg/mL; p < 0.005). Conclusions: Ea is a reliable parameter of right ventricular afterload and helps discriminate the risk of acute RVF after LVAD implantation. The combined analysis of Ea and central venous pressure can also risk stratify patients undergoing LVAD implantation for the development of RVF.